Author Archive

Home »

SSR Index of Current-Quarter Healthcare Demand Growth: Interim 2Q14 Estimates

We expect 6.8% (nominal) y/y growth in US health services demand during 2Q14, the product of 5.2% growth in demand intensity and 1.5% growth in price. Our estimate of demand intensity is sharply higher in 2Q14 – reflecting an expectation

Read More

Net HIE Premiums Growing Faster Than Incomes; This is Likely to Accelerate

The average premium increase thus far proposed by health insurance exchange (HIE) plans for 2015 is 10%; this compares to 4% to 5% expected income growth for subsidy eligible households We encounter a common misperception that the Affordable Care Act

Read More

Early Look at 2015 HIE Rates: Avg. Increase = 10%

11 states have disclosed insurers’ proposed rates for plans to be sold on the health insurance exchanges (HIEs) in 2015. The enrollment-weighted average rate increase thus far is 10.0%. These states’ 2014 HIE beneficiaries represent 14.6% of nationwide 2014 HIE

Read More

Large Pharma’s ‘Established’ & ‘Growth’ NEWCOs: A Solomonic Path to More Efficient R&D?

We divided the large cap pharmaceutical companies into ‘established’ and ‘growth’ NEWCOs; we then compared the combined value of the ‘established’ and ‘growth’ NEWCOs to the legacy parent companies, and found no compelling evidence to believe the combined NEWCO values

Read More

SSR Health New Product Approval Portfolios & Supporting Data Update

Drug, biotech, and research-based spec pharma stocks tend to outperform their peers in the year or so before and after regulatory actions (‘PDUFA’ dates) on major new products, with a large portion of total risks being concentrated in the days

Read More

SSR Index of Current-Quarter Healthcare Demand Growth: Initial 2Q14 Estimates

We expect 7.1% (nominal) y/y growth in US health services demand during 2Q14, the product of 5.5% growth in demand intensity and 1.5% growth in price. Our estimate of demand intensity are sharply higher in 2Q14, and reflect an expectation

Read More

Poor R&D Productivity as a Self-Inflicted Injury: Who’s Missing the Most Toes, and Why

R&D productivity can be measured, and thus managed, far better than is reflected in current practice Using metrics produced with a combination of US patent data and company disclosures, we calculate / identify: economic returns to R&D spending (the relationship

Read More

BIG Monkeys & a Looming Intervention: Pharma’s US Pricing Addiction

US real pricing gains for drugs sold in the US are driving nearly all of the traditional large cap pharmaceuticals industry’s growth. Only Roche and JNJ have US sales growth that exceeds the rate of US price growth, i.e. every

Read More

Co-Pay Cards & the Stalling of Drug Rebate Growth Part II – The HIE ‘Test Case’

Drug benefits on the health insurance exchanges (HIEs) are far less generous than under employer-sponsored insurance (ESI); in many cases HIE beneficiaries will not fill prescriptions without generous support from manufacturers’ co-pay card programs If manufacturers allow their co-pay cards

Read More

Relative Price & Value of pre-Phase III Pipelines for the 23 Largest Drug & Biotech Companies – Updated View

Using patent data, we estimate the relative ‘true economic’ value of companies’ pre-phase 3 (aka ‘hidden’ pipelines), then compare these estimates to the apparent market capitalization of these same pipelines. Our fundamentally based estimate of a given pipeline’s value often

Read More
test